30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818605862220988416 |
|---|---|
| author | Arnab Basu Eddy Yang Yash Suri Lakshminarayan Nandagopal Mollie Deshazo Lyse Norian |
| author_facet | Arnab Basu Eddy Yang Yash Suri Lakshminarayan Nandagopal Mollie Deshazo Lyse Norian |
| author_sort | Arnab Basu |
| collection | DOAJ |
| first_indexed | 2024-12-16T14:01:42Z |
| format | Article |
| id | doaj.art-7dc9620ea7a74b5e8d4e004b296d8294 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-16T14:01:42Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-7dc9620ea7a74b5e8d4e004b296d82942022-12-21T22:29:04ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.003030 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinomaArnab Basu0Eddy Yang1Yash Suri2Lakshminarayan Nandagopal3Mollie Deshazo4Lyse Norian51University of Alabama at Birmingham, Birmingham, AL, USAAff1 grid.265892.20000000106344187University of Alabama at Birmingham Birmingham AL USA 1University of Alabama at Birmingham, Birmingham, AL, USA1University of Alabama at Birmingham, Birmingham, AL, USA1University of Alabama at Birmingham, Birmingham, AL, USA1University of Alabama at Birmingham, Birmingham, AL, USA |
| spellingShingle | Arnab Basu Eddy Yang Yash Suri Lakshminarayan Nandagopal Mollie Deshazo Lyse Norian 30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma Journal for ImmunoTherapy of Cancer |
| title | 30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma |
| title_full | 30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma |
| title_fullStr | 30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma |
| title_full_unstemmed | 30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma |
| title_short | 30 NLR (neutrophil lymphocyte ratio) and PLR (platelet lymphocyte ratio) changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma |
| title_sort | 30 nlr neutrophil lymphocyte ratio and plr platelet lymphocyte ratio changes as a predictor of eventual treatment failure and death on nivolumab therapy in renal cell carcinoma |
| work_keys_str_mv | AT arnabbasu 30nlrneutrophillymphocyteratioandplrplateletlymphocyteratiochangesasapredictorofeventualtreatmentfailureanddeathonnivolumabtherapyinrenalcellcarcinoma AT eddyyang 30nlrneutrophillymphocyteratioandplrplateletlymphocyteratiochangesasapredictorofeventualtreatmentfailureanddeathonnivolumabtherapyinrenalcellcarcinoma AT yashsuri 30nlrneutrophillymphocyteratioandplrplateletlymphocyteratiochangesasapredictorofeventualtreatmentfailureanddeathonnivolumabtherapyinrenalcellcarcinoma AT lakshminarayannandagopal 30nlrneutrophillymphocyteratioandplrplateletlymphocyteratiochangesasapredictorofeventualtreatmentfailureanddeathonnivolumabtherapyinrenalcellcarcinoma AT molliedeshazo 30nlrneutrophillymphocyteratioandplrplateletlymphocyteratiochangesasapredictorofeventualtreatmentfailureanddeathonnivolumabtherapyinrenalcellcarcinoma AT lysenorian 30nlrneutrophillymphocyteratioandplrplateletlymphocyteratiochangesasapredictorofeventualtreatmentfailureanddeathonnivolumabtherapyinrenalcellcarcinoma |